Gene · 10987
Papers2,142
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,142
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The role of hepatitis B virus genome variations in HBV-related HCC: effects on host signaling pathways. | Front Microbiol | 2023 | 37588887 | PubTator, text mining | PubMed |
| The deubiquitinase EIF3H promotes hepatocellular carcinoma progression by stabilizing OGT and inhibiting ferroptosis. | Cell Commun Signal | 2023 | 37559097 | PubTator, text mining | PubMed |
| Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy. | Front Immunol | 2023 | 37554324 | PubTator, text mining | PubMed |
| Pre-mRNA splicing-associated diseases and therapies. | RNA Biol | 2023 | 37528617 | PubTator, text mining | PubMed |
| The CSN5/HSF/SPI1/PU.1 Axis Regulates Cell Proliferation in Hypocellular Myelodysplastic Syndrome Patients. | J Pediatr Hematol Oncol | 2023 | 37526438 | PubTator, text mining | PubMed |
| Exploring the Molecular Targets for the Antidepressant and Antisuicidal Effects of Ketamine Enantiomers by Using Network Pharmacology and Molecular Docking. | Pharmaceuticals (Basel) | 2023 | 37513925 | PubTator, text mining | PubMed |
| Targeted Protein Degradation: Principles and Applications of the Proteasome. | Cells | 2023 | 37508510 | PubTator, text mining | PubMed |
| Evaluation of the Involvement of Heme Oxygenase-1 Expression in Discoid Lupus Erythematosus Lesions. | Antioxidants (Basel) | 2023 | 37507892 | PubTator, text mining | PubMed |
| E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies. | Front Immunol | 2023 | 37497216 | PubTator, text mining | PubMed |
| Comprehensive analysis of the progression mechanisms of CRPC and its inhibitor discovery based on machine learning algorithms. | Front Genet | 2023 | 37476415 | PubTator, text mining | PubMed |
| The C-terminal tail of CSNAP attenuates the CSN complex. | Life Sci Alliance | 2023 | 37460146 | PubTator, text mining | PubMed |
| A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses. | Front Oncol | 2023 | 37456238 | PubTator, text mining | PubMed |
| miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia. | Cell Death Discov | 2023 | 37454155 | PubTator, text mining | PubMed |
| Hesperidin, a Bioflavonoid in Cancer Therapy: A Review for a Mechanism of Action through the Modulation of Cell Signaling Pathways. | Molecules | 2023 | 37446814 | PubTator, text mining | PubMed |
| Dynamic changes in pathology and PD-L1 expression in a patient with metastatic lung adenocarcinoma who received pembrolizumab therapy followed by two salvage surgeries two years later: A case report. | Thorac Cancer | 2023 | 37416998 | PubTator, text mining | PubMed |
| Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy. | Front Immunol | 2023 | 37415977 | PubTator, text mining | PubMed |
| The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications. | Exp Hematol Oncol | 2023 | 37415251 | PubTator, text mining | PubMed |
| Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. | Genes Dis | 2023 | 37397537 | PubTator, text mining | PubMed |
| Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy. | Genes Dis | 2023 | 37396527 | PubTator, text mining | PubMed |
| USP51/PD-L1/ITGB1-deployed juxtacrine interaction plays a cell-intrinsic role in promoting chemoresistant phenotypes in non-small cell lung cancer. | Cancer Commun (Lond) | 2023 | 37386737 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10987/papers?page=9